Background: YM-215389 and YM-228855 are thiazolidenebenzenesulfonamide (TBS) derivatives and novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) that inhibit not only wild-type, but also the K103Nand Y181C-substituted reverse transcriptase (RT) of HIV type-1 (HIV-1). Methods: To characterize the binding modes of the TBS derivatives in detail, the anti-HIV-1 activities of YM-215389 and YM-228855 against various NNRTIresistant clones were examined. Docking studies with HIV-1 RT were also performed. Results: YM-215389, which effectively inhibits various NNRTI-resistant clones, interacted with L100, K103, V106 and Y318 through the benzene ring and with E138, V179, Y181, Y188 and W229 through the thiazole ring. A single amino acid substitution confers only moderate resistance to YM-215389; indeed, four amino acid substitutions ( V106L, V108I, E138K and L214F) were necessary for highlevel resistance. Although the activity of YM-228855, a derivative of YM-215389 that has two bulky and rigid cyano-moieties on the benzene ring, was 10× more potent against HIV-1 than YM-215389, its anti-HIV-1 activity was readily reduced with single substitutions as with Y181I and K103N. Conclusions: These results provide structural information for optimizing the TBS derivatives in an attempt to construct ideal NNRTIs that maintain anti-HIV-1 activity to various HIV-1 variants.
Introduction
Y181C variant [9] [10] [11] . The K103N variant and NNRTIrelated double mutation, for example, K103N plus Y188L, carry high resistance to EFV [12, 13] . Therefore, the development of NNRTIs, which maintain anti-HIV-1 activity against various NNRTI-resistant variants, is important to sustain long-term HIV-1 chemotherapy.
We recently reported that novel NNRTIs, the thiazolidenebenzenesulfonamide (TBS) derivatives YM-215389 and YM-228855 ( Figure 1A) , inhibited HIV-1 replication, including that of the K103N-and Y181C-substituted variants [14] [15] [16] . To elucidate YM-215389 and YM-228855 binding to HIV-1 RT, the anti-HIV-1 activity of these two TBS derivatives against NNRTI-resistant clones was measured. In addition, genotypic and phenotypic analyses of variants resistant to YM-215389 and YM-228855, as well as docking studies on these TBS derivatives with HIV-1 RT were performed. Our data provide useful structural information to optimize TBS derivatives for the ideal NNRTIs that maintain anti-HIV-1 activity to various HIV-1 variants.
Methods

Antiviral agents
AZT was purchased from Sigma (St Louis, MO, USA). NNRTIs, NVP, EFV, YM-215389 and YM-228855 were synthesized as described previously [14, 17] .
Cells
MT-2 and 293T cells were grown in RPMI 1640 medium and Dulbecco's modified Eagle's medium, respectively, supplemented with 10% fetal calf serum, 2 mM l-glutamine, 100 U/ml penicillin and 50 µg/ml streptomycin. HeLa-CD4-LTR/β-gal cells [18] were used to determine drug susceptibility.
Viruses and construction of HIV-1 clones
The laboratory strain, HIV-1 LAI , propagated in MT-2 cells, was employed for induction of the resistant variants. Recombinant infectious HIV-1 clones carrying various substitutions in the RT gene were generated as described previously [19] . Briefly, desired mutations were introduced into the XmaI-NheI region (759 base pairs) of pTZNX1, which codes for Gly-15 to Ala-267 of HIV-1 RT (strain BH10), by site-directed mutagenesis. The XmaI-NheI fragment was inserted into a pNL101-based plasmid, pNL-RT, generating various molecular clones with the desired mutations. The presence of the intended substitutions and the absence of unintended substitutions in the infectious clones were confirmed by sequencing.
Each molecular clone was transfected into 293T cells and cocultured with MT-2 cells after 24 h. When an extensive cytopathic effect was observed, cell-free supernatants were harvested, titrated for virus and stored at -80°C until use. An infectious clone generated from pNL-RT served as a wild-type infectious clone (HIV-1 WT ).
Determination of drug susceptibility
The sensitivity of infectious clones to various RT inhibitors was determined using the multinuclear activation of a galactosidase indicator (MAGI) assay [18] with some modifications [19, 20] . Briefly, HeLa CD4-LTR/β-gal cells (10 4 cells/well) were plated in 96-well flat microtitre culture plates. On the following day, the medium was aspirated and the cells were inoculated with the HIV-1 clones (70 MAGI units/well, which yielded 70 blue cells after 48 h of incubation) and cultured in the presence of various concentrations of drugs in fresh medium. The blue cells in each well were counted 48 h after viral exposure. All experiments were performed in triplicate.
Induction of resistant variants
MT-2 cells and HIV-1 LAI were used for induction of resistant variants using a dose-escalating method [20, 21] . Each selection experiment began at the 50% effective concentration (EC 50 ) determined by the MAGI assay. When extensive cytopathic effects were observed, the concentration was increased to twice the initial concentration. The sequence of the RT region was determined using direct sequencing of the proviral DNA from the infected MT-2 cells.
Molecular modelling and docking studies
Three dimensional structures of YM-215389 and YM-228855 were generated using the previously determined crystal structure of the parental compound, N-(5-tert-butyl-3,4-dimethyl-1,3-thiazol-2(3H)-ylidene)-3-nitrobenzenesulfonamide [14, 17] as the template. Docking studies of the compounds and HIV-1 RT were performed using the GOLD program [22] on the HIV-1 RT structure obtained from the Protein Data Bank (PDB) [23] for the 1HNV entry [24] . Structures of reference compounds, NVP and EFV (PDB code 1FK9 and 1VRT [25] , respectively), were also obtained from the PDB. In these models, the amino acid substitution docking score for RT and the reference compounds were calculated using the SYBYL program, version 6.8 (Tripos, St Louis, MO, USA). To estimate the flexibility of YM-215389, we analysed the torsion angle distributions of the single rotation bond between the thiazole ring and the benzene ring using the Cambridge Structural Database (CSD) [26] .
Results
Anti-HIV-1 activity of the TBS derivatives to NNRTI-resistant clones
The anti-HIV-1 activities of YM-215389 and YM-228855 against recombinant viruses with major NNRTI-resistant substitutions (deposited in the Stanford HIV Drug Resistance Database [27, 28] ), were measured using the MAGI assay (Table 1) . YM-215389 and YM-228855 inhibited six major substituted variants: HIV-1 A98G , HIV-1 K103N , HIV-1 V106A , HIV-1 Y181C , HIV-1 V189I and HIV-1 G190A with EC 50 values at submicromolar concentrations. YM-215389 potently inhibited HIV-1 V106A , HIV-1 Y181C and HIV-1 V189I clones with EC 50 values similar to that against HIV-1 WT (20 nM), but its anti-HIV-1 activity against HIV-1 A98G , HIV-1 K103N and HIV-1 G190A clones were somewhat less (7-33-fold resistance of HIV-1 WT ). YM-228855, a derivative of YM-215389 that has two cyano-moieties on the phenyl ring, showed extremely potent anti-HIV-1 activity against HIV-1 WT (EC 50 =2.0 nM). The anti-HIV-1 activity of YM-228855 against HIV-1 A98G , HIV-1 K103N and HIV-1 Y181C clones were less than against HIV-1 WT (17-, 87-and 54-fold, respectively). Interestingly, the anti-HIV-1 activity of YM-228855 against HIV-1 V106A and HIV-1 V189I was slightly more than against HIV-1 WT . Overall, the YM-215389 range of antiviral efficacy against NNRTI-resistant variants was larger than NVP and similar to EFV. However, the YM-228855 range of antiviral efficacy was similar to NVP, but worse than EFV and YM-215389 (Table 1 ).
Isolation and genotypic analyses of variants resistant to TBS derivatives
During serial passage (P) in the presence of YM-215389, at concentrations of <0.1 µM, a partial substitution of isoleucine for valine (V106V/I) and L214F substitutions were found at P-11 ( Figure 1B) . At P-16, V106V/I changed to solely V106I and additional partial substitutions, V108V/I and E138E/K, were identified. At P-20, at a concentration of >20 µM, the substitution of V106I changed to V106L and the partial substitutions V108V/I and E138E/K were completely changed to V108I and E138K, which resulted in a V106L, V108I, E138K and L214F combined mutant, HIV-1 YM-215389 R .
In the presence of YM-228855, at concentrations of <0.1 µM, T165I and L214F substitutions were found at P-16 ( Figure 1C ). These substitutions have not been reported as NNRTI-resistant substitutions, but are described as polymorphisms in the HIV-1 genome [29, 30] . At P-24, partial substitutions for wild-type amino acids, V179V/D and Y188Y/C, were found in addition to the T165I and L214F mutations. However, at P-28, V179D disappeared and Y181Y/I emerged. At P-31, at concentrations >50 µM, T165I and Y188Y/C disappeared and the only detectable substitutions were Data represent the mean values of at least three independent assays. The 50% antiviral effective concentration (EC 50 ) was determined from the multinuclear activation of a galactosidase indicator assay. *Fold of resistance compared with the HIV type-1 wild-type infectious clone (HIV-1 NL-WT .). † Resistance >10-fold. NNRTI, non-nucleoside reverse transcriptase inhibitor. other. Both variants showed a slight reduction in susceptibility to EFV (7-11-fold reduction). However, they showed different resistance phenotypes to NVP; HIV-1 YM-228855 R reduced its susceptibility to NVP >15-fold stronger than HIV-1 YM-215389 R .
Effect of substitutions observed during the selection
To examine which substitution is involved in the development of YM-215389 and YM-228855 resistance, various molecular clones containing substitutions observed during the resistant variant selection were constructed. Among the substitutions obtained during HIV-1 YM-215389 R selection, V106I, V106L and L214F substitutions did not confer any resistance to NVP or EFV ( Table 1 ). The V106I substitution did not confer any resistance to TBS derivatives, whereas the V106L substitution resulted in modest resistance to YM-215389 and YM-228855 (16-and 15-fold reductions, respectively). The V108I substitution did not induce high resistance to TBS derivatives; however, it enhanced 
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YM-215389 and YM-228855 resistance by E138K substitution. V108I and E138K substitutions are also observed during in vitro experiments with combination regimens containing EFV [31, 32] . Comparisons of V106I/V108I/E138K with V106L/V108I/E138K also indicated that V106L enhanced drug resistance to TBS derivatives. This is consistent with observations made during selection; the V106I substitution was observed at P-16 (2.56 µM), but was replaced by V106L at P-20 (40 µM; Figure 1B ). According to the Stanford HIV Drug Resistance Database, V106I is a common polymorphism that does not decrease NNRTI susceptibility. In contrast, V016L is rarely observed and only confers potential low-level resistance to NVP and delavirdine. Therefore, V106L appears to be a characteristic mutation for YM-215389. The L214F substitution observed in many HIV-1 strains isolated from drug-naive patients [29] did not show resistance to any of the compounds tested. However, L214F enhanced resistance to YM-215389 when combined with V106L/V108I/E138K (Table 1 ). These results suggest that for the development of YM-215389 resistance, the primary mutation is V106L; however, other mutations are also needed to obtain stronger resistance ( Table 1) . L214F also played an important role in enhancing resistance to YM-228855 (Y181I with Y181I/L214F; Table 1 ).
Docking study
The modes in which YM-215389 and YM-228855 bind to HIV-1 RT were estimated using the GOLD program. Our simulation indicated that their binding modes are almost the same. As shown in Figures 2A-2D , 'the body' is formed by the hydrophilic sulfonamide faces outside of the NNRTI-BHP and 'the wings' are formed by the hydrophobic thiazole and benzene rings where they interact with the hydrophobic amino acids in the NNRTI-BHP, such as L100, K103, V106, Y318, E138, V179, Y181, Y188 and W229. YM-215389 interacts with L100, K103, V106 and Y318 through the benzene ring and with E138, V179, Y181, Y188 and W229 through the thiazole ring ( Figure 2E ). In our model, there was no hydrogen bonding between YM-215389 or YM-228855 and NNRTI-BHP. The T165 and L214 substitutions were located outside of the NNRTI-BHP and each had a slight effect on the binding of TBS derivatives to HIV-1 RT.
Structural comparison of TBS derivatives with NVP and EFV
The structures of YM-215389 and YM-228855 elucidated by our docking simulations were compared with those of NVP (1FK9) and EFV (1VRT). The TBS derivatives had a 'butterfly structure', like NVP and EFV ( Figures 3A & 3B) [33, 34] . The thiazole and benzene rings, and the sulfonamide region constitute the butterfly's left wing, right wing and body, respectively. Superimposition of the TBS derivatives' figures onto those of NVP and EFV shows that the wing and body sizes are similar to identical ( Figure 3A ). This indicates that TBS derivatives interact with the NNRTI-BHP in a manner similar to that of NVP and EFV.
Flexibility of TBS
In the CSD, 24 compounds with a thiazole ringsulfonamide-benzene ring are deposited and were subjected to analysis of their torsion angles at C1-N2-S3-C4. The torsion angles were distributed between -123° to -64° and 71° to 129°. Conformational preferences for YM-215389 are depicted in Figure 4 . Because the benzene ring must be in the upright position (as depicted in Figure 2 ) in order to interact with NNRTI-BHP, the torsion angle distribution of the wing-angle was estimated to be 71 to 129°, which suggests that the sulfonamide bond can be rotated intermediately.
Discussion
Currently available NNRTIs interact with the NNRTI-BHP close to the HIV-1 RT active site [35, 36] . This common binding pocket results in cross-resistance among both first-and second-generation NNRTIs. For example, the K103N mutation located at the entrance to the NNRTI-BHP [37, 38] reduces susceptibility to various NNRTIs. The transformation of the linearly charged amino acid lysine into uncharged and branched asparagine increases pocket volume and decreases interaction Data represent the mean values of at least three independent assays. The 50% antiviral effective concentration (EC 50 ) was determined from the multinuclear activation of a galactosidase indicator assay. *Fold of resistance compared with the HIV type-1 wild-type infectious clone (HIV-1 NL-WT ). NNRTI, non-nucleoside reverse transcriptase inhibitor.
with NNRTIs. It also stabilizes the unliganded closed conformation of the NNRTI-BHP [9, 34] . For YM-215389, the effect of K103N mutation on its anti-HIV-1 activity was smaller than NVP, EFV and YM-228855 (Table 1 ). In fact, four amino acid substitutions were required for YM-215389 to develop strong resistance (>500-fold). Interestingly, all substituted mutants observed during HIV-1 YM-215389 R selection increased the susceptibility to AZT. This means that the emergence of resistance to YM-215389 does not occur readily, especially when the drug is used in combination with AZT. These results suggest that YM-215389 is a valuable lead compound in the search for next generation NNRTIs. The docking study showed that YM-215389 interacts hydrophobically with multiple amino acids in NNRTI-BHP, that is, YM-215389 interacts uniformly with L100, K103, V106 and Y318 through the benzene ring, and with E138, V179, Y181, Y188 and W229 through the thiazole ring (Figures 2A,  2B & 2E) . A single amino acid substitution over a large area within the NNRTI-BHP confers only moderate resistance to YM-215389 (Table 1) . YM-215389 is thought to maintain its anti-HIV-1 activity to major NNRTI-resistant mutants by adjusting the hydrophobic interactions with NNRTI-BHP via a sulfonamide backbone that can be rotated intermediately. The anti-HIV-1 activity of YM-228855 (EC 50 =2 nM) was more potent than that of YM-215389 (EC 50 =20 nM). However, its potent anti-HIV-1 activity was strongly reduced by single amino acid substitutions (Y181I, K103N and Y181C substitutions resulted in 540-, 87and 54-fold reductions, respectively). These results suggest that the cyano-moieties on the benzene ring of YM-228855 contribute to the enhanced anti-HIV-1 activity, but its protruding character restricts conformational adjustment with NNRTI-BHP.
The advantage of conformational adaptability has also been demonstrated with another NNRTI [39] . A diarylpyrimidine derivative, etravirine (TMC125-R165335) that inhibits various NNRTI-resistant clones with single amino acid substitutions, binds to the NNRTI-BHP using several binding modes. Cocrystallization of RT with etravirine results in resolution of only 6-8 Å (crystal grams), even when 
A B
C D e f using high-intensity synchrotron radiation, because the conformations corresponding with RT and etravirine that coexist in the crystal are different [40] . Like etravirine, YM-215389 has an intermediately rotatable sulfonamide backbone, which allows for more conformational adaptability than NVP and EFV can achieve. This is because NVP has a highly rigid dihydrodipyridodiazepine (triple ring) backbone and EFV has a relatively rigid 4-alkynyldihydrobenzoxazine-containing triple bond between its body and left wing. It has also been reported that inhibitors carrying molecularly flexible groups tend to be able to adapt to mutated enzymes. For instance, tenofovir (9-R-2phosphonomethoxypropyl adenine [PMPA]), an acyclic NRTI, inhibits various types of drug resistance to HIV-1 variants both in vitro and in vivo [41, 42] . PMPA has a highly flexible acyclic sugar compared with other NRTIs, for example, 2′,3′-dideoxyinosine, which confers the advantages of NRTIs [43] . PMPA can bind even to a mutated 3′-OH binding site, for example, K65, R72, Y115 and Q151, and be incorporated into the elongating primer end to block it. The incorporated PMPA can also escape excision by ATP. Thus, PMPA effectively inhibits viral DNA synthesis mediated by RT with resistance mutations. It has also been reported that the flexible HIV-1 protease inhibitor, JE-2147, which contains a P2′ benzylamide group with two rotatable bonds, is able to inhibit various protease inhibitorresistant variants. However, the inflexible derivative, JE-533, which contains a t-butylamide group with only one rotatable bond at this position, fails to suppress the resistant variants [44] .
In this report, the anti-HIV-1 activities of YM-215389 and YM-228855 against various substituted variants were investigated. The data suggest that conformational adaptability of hydrophobic interactions is important for enabling NNRTIs to maintain their anti-HIV activity against various HIV-1 variants. Therefore, YM-215389 is considered to be a promising lead compound for the next generation of NNRTIs. The flexibility of thiazolidenebenzenesulfonamide derivatives were estimated from 24 compounds with a thiazole ring-sulfonamide-benzene ring deposited in the Cambridge Structural Database [26] . The estimated torsion angles of C1-N2-S3-C4 are shown.
